Log in

OTCMKTS:ABLYFAblynx Stock Price, Forecast & News

$50.63
0.00 (0.00 %)
(As of 04/30/2019)
Add
Compare
Today's Range
$50.63
Now: $50.63
$50.63
50-Day Range
$50.63
MA: $50.63
$50.63
52-Week Range
$12.50
Now: $50.63
$55.04
VolumeN/A
Average VolumeN/A
Market Capitalization$3.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.
Read More
Ablynx logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ABLYF
Previous SymbolNASDAQ:ABLYF
CUSIPN/A
CIKN/A
Phone329-262-0000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.73 million
Book Value$2.71 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$3.81 billion
Next Earnings DateN/A
OptionableNot Optionable
$50.63
0.00 (0.00 %)
(As of 04/30/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive ABLYF News and Ratings via Email

Sign-up to receive the latest news and ratings for ABLYF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions

How has Ablynx's stock been impacted by COVID-19 (Coronavirus)?

Ablynx's stock was trading at $50.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABLYF stock has increased by 0.0% and is now trading at $50.63.
View which stocks have been most impacted by Coronavirus
.

Has Ablynx been receiving favorable news coverage?

Headlines about ABLYF stock have been trending very negative on Sunday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ablynx earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Ablynx
.

Who are some of Ablynx's key competitors?

Who are Ablynx's key executives?

Ablynx's management team includes the following people:
  • Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
  • Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
  • Mr. Piet Houwen, Chief Operations Officer
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer
  • Lies Vanneste, Director of Investor Relations

What is Ablynx's stock symbol?

Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."

How do I buy shares of Ablynx?

Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ablynx's stock price today?

One share of ABLYF stock can currently be purchased for approximately $50.63.

How big of a company is Ablynx?

Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year.

What is Ablynx's official website?

The official website for Ablynx is www.ablynx.com.

How can I contact Ablynx?

Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.